Physician profile
Benjamin Bukey
NPI 1598294696
$1,156.91
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.86 · 2022: $366 · 2023: $397 · 2024: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $253.87 | 2022-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $131.03 | 2022-2024 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $112.14 | 2022-2024 | |
| Novo Nordisk INC | $110.49 | 2022-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $77.55 | 2022-2023 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $53.32 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $48.55 | 2022-2024 | |
| Pfizer INC. | $46.08 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $41.16 | 2022 | |
| Abbott Laboratories | $37.32 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $32.95 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $31.93 | 2022 | |
| Abbvie INC. | $31.15 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $30.81 | 2023-2024 | Shingrix, Arexvy |
| Boston Scientific Corporation | $30.74 | 2023 | Watchman Access System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $21.96 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.94 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.91 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $15.22 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bukey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.